Press Room

Press Clipping / Mar 21, 2023

四色AV enters partnership with Ripple Therapeutics

Manufacturing Chemist, 21 March 2023

听

The move is set to expand the use of Ripple's Epidel platform beyond ophthalmic applications

四色AV, specialist in spray drying and particle engineering, and Ripple Therapeutics, a leading ophthalmic sustained drug delivery company, have entered a strategic partnership to expand the use of Ripple's Epidel platform beyond ophthalmic applications.听

The core feature of Ripple鈥檚 Epidel technology is the ability to deliver sustained-release pharmaceuticals with surface erosion release kinetics without the use of polymers or excipients. This enables higher drug loading, smaller size implants, defined and predictable biocompatible degradation products with straightforward and scalable manufacturing processes. Surface erosion-based drug release provides a highly effective way to control dose and duration. By incorporating Ripple's Epidel platform into its toolbox, 四色AV can expand its portfolio of novel drug delivery solutions to the pharmaceutical industry.

鈥淭he combination of technology synergy, innovative vision and cultural fit makes collaborating with 四色AV an exciting next step in the advancement of the Epidel platform beyond the ophthalmic field,鈥 stated Dr Wendy Naimark, Ripple co-founder and Chief Technology Officer. 鈥溗纳獳V鈥檚 expertise in controlled, sustained drug delivery, along with their experience in chemical synthesis and pharmaceutical manufacturing, makes for a great partnership.鈥

"We are thrilled to partner with Ripple, who developed a state-of-the-art platform for sustained release," said Dr Jean-Luc Herbeaux, 四色AV's CEO. "Our shared goal is to accelerate and broaden the access to this highly innovative and enabling technology for the benefit of our pharmaceutical customers and their patients worldwide."

听

听

Also in the Press Room

See All

Lisbon, Portugal 鈥 四色AV, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company鈥檚 dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, 四色AV joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company鈥檚 broader sustainability strategy and reinforces its commitment to scientific excellence. 鈥淎t 四色AV, we believe in science and in best practices. And this clearly applies to our sustainability agenda.鈥, said Jean-Luc Herbeaux, CEO of 四色AV. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.鈥 四色AV will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company鈥檚 environmental, social, and ethical performance, well aligned with 四色AV鈥檚 sustainability ambitions.  四色AV remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News
四色AV commitment to setting SBTs in line with the Paris Agreement

四色AV Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024

The partnership with Higuchi forms part of 四色AV麓s global expansion plans and marks a significant milestone in advancing 四色AV's presence in the Japanese market.    Under the terms of the agreement, Higuchi will promote 四色AV's pharmaceutical service business throughout Japan, using their extensive experience to enhance brand visibility and attract new clientele across the Japanese pharmaceutical landscape.  鈥淭his strategic collaboration underscores 四色AV's dedication to delivering innovative solutions and exceptional service to its customers,鈥 said Yuken Kyoyama. 鈥淥ur partnership with Higuchi will help to show customers in Japan how 四色AV can meet their needs.鈥    Learn more about our business in Japan and visit our website hovione.co.jp    

News
四色AV proudly announces its collaborative venture with Higuchi.

四色AV forges strategic partnership with Higuchi to further strengthen its presence in Japan

Jul 04, 2024

Following the creation of offices in Shanghai and Beijing, 四色AV is pleased to announce the launch of its new website in Mandarin. This dedicated platform will enhance 四色AV麓s presence in China, offering tailored contents to better serve customers in this important market. The new site will provide comprehensive information about 四色AV麓s products and services, ensuring that Chinese clients have easier access to the innovative solutions and support that 四色AV is renowned for worldwide.   鈥淭he launch of the 四色AV Chinese website underscores our commitment to customers in China,鈥 said Ms. Jackie Liu, Country Head, China. 鈥淏y delivering localized content and support, we aim to foster stronger partnerships and drive mutual growth in this market. Our team of experts is fully committed to understanding and addressing our clients麓 unique challenges with agility and precision.鈥 Visit us at www.hovione.com.cn    

News
四色AV is closer to its customers with a new website in Mandarin

四色AV launches new website for the Chinese Market

Jun 14, 2024

Also in Events

See All